Welcome to our dedicated page for Moderna SEC filings (Ticker: MRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Moderna, Inc. filings document the regulatory, financial and governance record of a commercial-stage mRNA biotechnology company. Form 8-K reports cover operating results, Regulation FD updates, FDA communications for investigational vaccine submissions, material agreements, patent-litigation settlements and financing arrangements tied to the company's vaccine and therapeutic portfolio.
Proxy and annual-meeting filings disclose board elections, shareholder voting results, executive compensation and governance provisions, including bylaw amendments. The filings also record capital-structure matters such as credit facilities, risk and disclosure controls around pipeline development, and formal updates related to products including Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX.
NABEL ELIZABETH G reported acquisition or exercise transactions in this Form 4 filing.
Moderna, Inc. director Elizabeth G. Nabel received an award of 8,371 restricted stock units, each convertible into one share of common stock. The units will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, contingent on her continued service.
Moderna, Inc. director Nader Francois reported equity compensation awards. He received 4,185 restricted stock units and a stock option for 6,454 shares of common stock, both granted at no cost on May 6, 2026. The option has a $48.79 exercise price and expires on May 6, 2036.
Both the stock option and the RSUs vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to his continued service. Following these grants, his reported derivative holdings from these awards match the granted amounts.
Moderna, Inc. director Elizabeth E. Tallett received a grant of 8,371 restricted stock units on May 6, 2026. Each restricted stock unit converts into one share of Moderna common stock.
The 8,371 units will vest in full on the earlier of May 6, 2027 or Moderna's next Annual Meeting of Shareholders, as long as she continues serving the company. Following this grant, her reported direct holding from this award is 8,371 restricted stock units.
Moderna, Inc. director Noubar Afeyan received a grant of stock options covering 12,908 shares of common stock. The options have an exercise price of $48.79 per share and expire on May 6, 2036.
According to the terms, this option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to his continued service. Following this grant, Afeyan holds 12,908 stock options directly in this award.
Moderna, Inc. director Sandra Horning increased her direct common stock holdings through equity compensation, not open‑market trading. On April 30, 2026, 16,233 restricted stock units converted into 16,233 shares of common stock on a one-for-one basis when the award vested in full. Following this exercise-and-hold event, she directly holds 18,585 Moderna common shares. The filing shows no stock sales, gifts, or tax-withholding dispositions, indicating a routine vesting of previously granted RSUs rather than a market purchase or sale.
Moderna director David M. Rubenstein exercised restricted stock units to receive 8,116 shares of Common Stock. The RSUs converted into common stock on a one-for-one basis and vested in full on April 30, 2026.
Following this vesting and conversion, Rubenstein directly holds 9,643 shares of Moderna common stock. The filing shows no open-market purchases or sales, only the automatic conversion of a stock-based compensation award into shares.
Moderna, Inc. director Hussain Abbas reported an exercise of restricted stock units (RSUs) and a related share sale. On April 30, 2026, RSUs covering 16,233 shares converted into common stock on a one-for-one basis when they vested in full. On May 1, 2026, Abbas sold 5,682 common shares at an average price of $46.63 per share under a pre-arranged Rule 10b5-1 trading plan to generate cash to cover tax liabilities from the RSU vesting. After these transactions, he directly owned 12,066 Moderna common shares.
Moderna, Inc. director Elizabeth G. Nabel acquired common shares through an equity award vesting. On April 30, 2026, 16,233 restricted stock units converted into 16,233 shares of common stock on a one-for-one basis. These RSUs vested in full on that date.
After the conversion, Nabel directly owned 19,317 shares of Moderna common stock. The filing shows an exercise or conversion of a derivative security related to compensation, with no open-market purchase or sale reported in this transaction.
Moderna director Nader Francois increased his direct equity stake through RSU vesting, not open-market buying. On April 30, 2026, 12,174 restricted stock units converted into the same number of Moderna common shares on a one-for-one basis at an exercise price of $0.00 per share.
These RSUs vested in full on that date, reflecting compensation rather than a market trade. Following the conversion, Francois directly owns 32,781 shares of Moderna common stock.